About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

0.3444 -0.0194 (-5.33%)
Streaming Delayed Price Updated: 11:31 AM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medicus Pharma Ltd. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancer 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer 
From Medicus Pharma Ltd
Via GlobeNewswire
Medicus Pharma (MDCX): A Small-Cap Biotech Making Moves in 2026
Via AB Newswire
News headline image
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma on Bloomberg World
Via ACCESS Newswire
News headline image
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
Via ACCESS Newswire
News headline image
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST
Via ACCESS Newswire
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
News headline image
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
Via ACCESS Newswire
These stocks are making the most noise in today's session. ↗
Via Chartmill
News headline image
American Lithium Minerals (OTC: AMLM) Targets Tokenized Commodities Opportunity Alongside MDCX, ASNS, EONR, ELPW Today!
Via AB Newswire
Topics Artificial Intelligence
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
New to The Street Broadcasts Tonight on Bloomberg Television at 6:30 PM EST - Shows 736, 737 and 738 Air Across the U.S., Latin America and MENA
Via ACCESS Newswire
Here are the top movers in Friday's session. ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Thursday's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma To Participate in the 38th Annual Roth Conference
Company Exec. Chairman & CEO in a fireside chat is expected to highlight the role of Skinject in an autosomal dominant rare disease, AI-enabled drug development strategy and partnering readiness 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) on Bloomberg Television Tonight at 6:30 PM EST
Via ACCESS Newswire
News headline image
New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd.
Via ACCESS Newswire
News headline image
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse... 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and... 
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American Association of Clinical Endocrinology (AACE) Annual meeting 2026 
From Medicus Pharma Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.